1. Academic Validation
  2. Recombinant anti-D for prevention of maternal-foetal Rh(D) alloimmunization: a randomized multi-centre clinical trial

Recombinant anti-D for prevention of maternal-foetal Rh(D) alloimmunization: a randomized multi-centre clinical trial

  • Obstet Gynecol Sci. 2020 May;63(3):315-322. doi: 10.5468/ogs.2020.63.3.315.
Rahul Vishwanath Mayekar 1 Gopalkrishna Vinayak Paradkar 2 Archana Anilkumar Bhosale 1 Rekha Sachan 3 Sumalatha Beeram 4 Ashok Ramachandra Anand 5 Shuchita Ramesh Mundle 6 Yamini Trivedi 7 Rashmi Md 8 Kiran Pandharinath Patole 9 Pradip Wamanrao Sambarey 10 Gautam Vinod Daftary 11 James John 11 Ganesh Harishchandra Divekar 11
Affiliations

Affiliations

  • 1 Department of Obstetrics and Gynaecology, Lokmanya Tilak Municipal Medical College & Lokmanya Tilak Municipal General Hospital, Mumbai, India.
  • 2 Department of Obstetrics and Gynaecology, Rajiv Gandhi Medical College & Chhatrapati Shivaji Maharaj Hospital, Thane, India.
  • 3 Department of Obstetrics and Gynaecology, King George's Medical University, Lucknow, India.
  • 4 Department of Obstetrics and Gynaecology, Gandhi Medical College and Hospital, Secunderabad, India.
  • 5 Department of Obstetrics and Gynaecology, Grant Medical College and Sir J.J. Group of Hospitals, Mumbai, India.
  • 6 Department of Obstetrics and Gynaecology, Government Medical College and Hospital, Nagpur, India.
  • 7 Department of Obstetrics and Gynaecology, AMC MET Medical College and Sheth LG General Hospital, Ahmedabad, India.
  • 8 Department of Obstetrics and Gynaecology, Apollo BGS Hospital, Mysore, India.
  • 9 Department of Obstetrics and Gynaecology, Dr. Vasantrao Pawar Medical College and Research Centre, Nashik, India.
  • 10 Department of Obstetrics and Gynaecology, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India.
  • 11 Clinical Research and Pharmacovigilance, Bharat Serums and Vaccines Limited, Navi Mumbai, India.
Abstract

Objective: To compare the efficacy and safety of recombinant anti-D (R-anti-D) with conventional polyclonal anti-D (Poly anti-D) in preventing maternal-fetal rhesus D (RhD) alloimmunization and to investigate the immunogenicity of R-anti-D.

Methods: This was a randomized, open-label, multi-center clinical trial conducted in RhD-negative pregnant women who did not receive antenatal anti-D who delivered RhD-positive babies and showed negative indirect Coombs tests (ICTs) at baseline. The women were randomized in a 2:1 ratio to R-anti-D or Poly anti-D groups and were administered 300 mcg (IM) of the corresponding drug within 72 hours of delivery. ICT was performed 72 hours, 90 days, and 180 days after anti-D injection. Serum samples were collected to check for the development of Antibodies against R-anti-D at days 90 and 180, using bridging enzyme-linked immunosorbent assay. The proportion of subjects who had positive ICT results at days 90 and 180 were compared between the groups using Fisher's exact test.

Results: A total of 144 women were randomized to the R-anti-D group and 71 to the Poly anti-D group. Three women in the R-anti-D and none in the Poly anti-D group had a positive ICT result at day 90. No woman in either group had positive ICT result at day 180. Both drugs were well tolerated with only 4 reports of adverse events in each group-all were mild, non-serious, and resolved without sequelae. No subject developed Antibodies against R-anti-D.

Conclusion: The studied R-anti-D is comparable in efficacy to conventional Poly anti-D and is safe and non-immunogenic.Trial Registration: Clinical Trials Registry of India Identifier: Trial Registration: Clinical Trials Registry of India Identifier: CTRI/2017/03/008101.

Keywords

Newborn hemolytic disease; Recombinant proteins; Rh isoimmunization; Rho(D) immune globulin.

Figures
Products